Techlife Capital

Flash Therapeutics is a biotechnology company based in Labège, France, specializing in gene and cell-based therapies through its proprietary lentiviral platform. Established in 2005 and formerly known as Vectalys SAS, the company focuses on developing advanced viral vector technologies to transduce difficult-to-transfect cells, including primary cells and stem cells. Flash Therapeutics offers a range of services, including gene silencing, gene over-expression, cell-based assay development, and protein expression. It also conducts preclinical trials for gene therapy and produces concentrated viral vectors for research purposes. The company is committed to creating innovative solutions for drug screening and the development of cellular and animal models to validate candidate genes.